Fig. 1From: Efficacy of sorafenib in BRAF-mutated non-small-cell lung cancer (NSCLC) and no response in synchronous BRAF wild type-hepatocellular carcinoma: a case reportLung: high power view of aggregate of primary lung adenocarcinoma cells a, with diffuse and intense nuclear staining for Thyroid transcription factor-1 (TTF-1). b. Liver: high power view of HCC, c, with a distinct granular cytoplasmic staining for HepPar-1, dBack to article page